Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent
Author:
Affiliation:
1. Qurient Incorporated, 16 Daewnagpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm5003606
Reference17 articles.
1. World Health Organization. Global Tuberculosis Control WHO Report 2012; WHO/HTM/TB/2012.6; 2012.
2. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
3. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
4. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
5. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Cited by 161 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment;European Journal of Medicinal Chemistry;2024-11
2. Insights into medicinal attributes of imidazo[1,2‐a]pyridine derivatives as anticancer agents;Archiv der Pharmazie;2024-09-02
3. A Review of Antibacterial Candidates with New Modes of Action;ACS Infectious Diseases;2024-07-17
4. The Structure–Antiproliferative Activity Relationship of Pyridine Derivatives;International Journal of Molecular Sciences;2024-07-11
5. Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity;ACS Medicinal Chemistry Letters;2024-03-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3